Cargando…

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing–remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield bioequivalent exposure to the active metabolite monomethyl fumarate; thus, efficacy/safety profiles are expected to be simi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naismith, Robert T, Wolinsky, Jerry S, Wundes, Annette, LaGanke, Christopher, Arnold, Douglas L, Obradovic, Dragana, Freedman, Mark S, Gudesblatt, Mark, Ziemssen, Tjalf, Kandinov, Boris, Bidollari, Ilda, Lopez-Bresnahan, Maria, Nangia, Narinder, Rezendes, David, Yang, Lili, Chen, Hailu, Liu, Shifang, Hanna, Jerome, Miller, Catherine, Leigh-Pemberton, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604551/ https://www.ncbi.nlm.nih.gov/pubmed/31680631 http://dx.doi.org/10.1177/1352458519881761

Ejemplares similares

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
por: Naismith, Robert T., et al.
Publicado: (2020)

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
por: Singer, Barry A, et al.
Publicado: (2023)

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study
por: Wray, Sibyl, et al.
Publicado: (2022)

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
por: Wundes, Annette, et al.
Publicado: (2021)

Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate
por: Gül, Sedat, et al.
Publicado: (2023)

Diroximel fumarate for multiple sclerosis
Publicado: (2022)

Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews
por: Gudesblatt, Mark, et al.
Publicado: (2022)

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study
por: Palte, Michael J., et al.
Publicado: (2019)

The DRF motif of CXCR6 as chemokine receptor adaptation to adhesion
por: Koenen, Andrea, et al.
Publicado: (2017)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2008)

Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients
por: Schriefer, Dirk, et al.
Publicado: (2020)

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study
por: Singer, Barry, et al.
Publicado: (2012)

Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis
por: Kuchimanchi, Mita, et al.
Publicado: (2022)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Expression Analysis of the TdDRF1 Gene in Field-Grown Durum Wheat under Full and Reduced Irrigation
por: Latini, Arianna, et al.
Publicado: (2022)

Risk Factors for Complications following Volar Locking Plate (VLP) Fixation of Unstable Distal Radius Fracture (DRF)
por: Zhu, Yanbin, et al.
Publicado: (2022)

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
por: Cuker, Adam, et al.
Publicado: (2019)

DRF 3188 a novel semi-synthetic analog of andrographolide: cellular response to MCF 7 breast cancer cells
por: Satyanarayana, Chitkala, et al.
Publicado: (2004)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis
por: Lager, Brittney, et al.
Publicado: (2022)

Chk1 Inhibition of the Replication Factor Drf1 Guarantees Cell-Cycle Elongation at the Xenopus laevis Mid-blastula Transition
por: Collart, Clara, et al.
Publicado: (2017)

Incidence and risk factors for surgical site infection following volar locking plating (VLP) of unstable distal radius fracture (DRF)
por: Meng, Hongyu, et al.
Publicado: (2022)

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence
por: Liseno, Jacob, et al.
Publicado: (2021)

Tracheal epithelium cell volume responses to hyperosmolar, isosmolar and hypoosmolar solutions: relation to epithelium-derived relaxing factor (EpDRF) effects
por: Fedan, Jeffrey S., et al.
Publicado: (2013)

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
por: Hauer, Larissa, et al.
Publicado: (2022)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
por: Nash, Richard A., et al.
Publicado: (2017)

17. Ultrasound-guided Supraclavicular Block (USGB) by Surgeon for ORIF of Distal Radius Fractures (DRF): A 6-year Experience with 1830 Consecutive Cases
por: Calva-Cerqueira, Daniel, et al.
Publicado: (2023)

Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
por: Nieto-Gómez, Pelayo, et al.
Publicado: (2023)

Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis
por: Mäurer, Mathias, et al.
Publicado: (2019)

Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
por: Lager, Brittney, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_87tgkint19eo32kva4kkqg5spk